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Background: Although the use of bortezomib alone and in combination with steroids has shown efficacy in AL
amyloidosis, its role in combination with high-dose melphalan and autologous stem cell transplantation (HDM/SCT)
is unknown. In this study, we evaluated bortezomib in combination with dexamethasone (BD) for induction
chemotherapy prior to HDM/SCT.
Methods: This was a single-center, prospective, randomized controlled trial comparing induction therapy consisting
of two BD cycles followed by HDM/SCT (BD + HDM/SCT) with HDM/SCT alone in the treatment of patients with
newly diagnosed AL amyloidosis. The hematological and organ responses of the patients were assessed every three
months post HDM/SCT.
Results: Fifty-six patients newly diagnosed with renal (100%), cardiac (57.1%), liver (7.1%), or nervous system (8.9%)
AL amyloidosis were enrolled in this study; 28 patients were assigned to each arm. Two patients died within
100 days of HDM/SCT (3.6% treatment-related mortality). The overall hematologic response rates in the BD + HDM/
SCT arm and HDM/SCT arm at three, six and twelve months were 78.5% versus 50%, 82.1% versus 53.5% and 85.7%
versus 53.5%, respectively. In the BD + HDM/SCT arm, 15 (53.5%) patients achieved a hematologic response after BD
and before HDM/SCT. An intention-to-treat analysis revealed a higher rate of complete remission in the BD + HDM/
SCT arm at both 12 and 24 months (67.9% and 70%, respectively) than with the HDM/SCT-only therapy (35.7% and
35%, respectively, P = 0.03). After a median follow-up of 28 months, the survival rates at 24 months post-treatment
start were 95.0% in the BD + HDM/SCT group and 69.4% in the HDM/SCT alone group (P = 0.03).
Conclusions: Our preliminary data suggest that the outcome of treating AL amyloidosis with BD induction and
HDM/SCT was superior to the outcome of the HDM/SCT treatment alone.
Trial registration: This trial has been registered at clinicaltrials.gov with the number NCT01998503.
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AL amyloidosis is the most common form of systemic
amyloidosis, and it arises from the production of mono-
clonal free light chains (FLCs) by a pathological plasma
cell clone [1]. The deposition of insoluble amyloid fibrils
in vital organs, such as the heart, kidney, liver, and nerves,
can lead to progressive organ dysfunction and death [2]. AL
amyloidosis is often devastating, and the median survival
rate of untreated patients with this lethal disease is only 10
to 14 months from diagnosis [3]. The treatment for AL
amyloidosis is aimed at reducing FLCs by eradicating the
plasma cells [4] that produce them, although the options
currently available for this treatment are limited [5].
AL amyloidosis treatments are based on existing multiple
myeloma therapies. Melphalan (MEL) and prednisone ad-
ministration was the first effective regimen developed for
AL amyloidosis; however, the treatment responses are typ-
ically slow and rarely result in complete remission [6,7]. An
Italian study combining MEL with high-dose dexametha-
sone (MDex) noted an impressive hematologic response
rate of 67% [8] and long-term remissions in AL amyloidosis
[9], and MDex is still considered a standard for non-study,
non-transplant intervention because of its low toxicity
profile [10]. Alternatively, intensive therapy with high-
dose MEL and autologous stem cell transplantation
(HDM/SCT) is effective in AL amyloidosis and can offer
durable remission in some patients [11,12]. However, only
25% of affected patients are eligible for this approach
[13,14], and the treatment-related mortality (TRM) with
HDM/SCT is high [11,15,16]. Accordingly, it is necessary
to identify modifications to the HDM/SCT procedure that
could improve outcomes in patients with AL amyloidosis.
Novel drugs, including thalidomide [17,18], lenalidomide
[19] and bortezomib [20] (alone or in combination with
dexamethasone), have recently proven to be effective in
the non-transplantation setting. Bortezomib is a reversible
proteasome inhibitor that has shown significant activity
in patients with multiple myeloma [21,22]. Indeed, several
studies have confirmed that bortezomib combined with
dexamethasone (BD) is an active and fast-acting regimen
for AL amyloidosis, even in pretreated patients [20,23-25].
However, the data regarding the toxicity and efficacy of BD
chemotherapy prior to HDM/SCT are limited for patients
with AL amyloidosis. Thus, to determine whether induc-
tion therapy with BD is advantageous in patients with
AL amyloidosis, we prospectively evaluated a therapeutic
regimen consisting of two cycles of BD chemotherapy
followed by HDM/SCT in a single-center study.
Methods
Patient eligibility
Patients with newly diagnosed AL amyloidosis were en-
rolled in this trial, which was approved by the institutional
ethical review board of Jinling Hospital. The participantsor their guardians provided written informed consent. All
patients had amyloid disease, which was confirmed by renal
biopsy and documented plasma cell dyscrasia; the AL amyl-
oidosis diagnosis and the assessment of organ involvement
were based on consensus criteria [26]. Patients who met
the three criteria for multiple myeloma (MM) diagnosis,
that is, clonal bone marrow plasma cells ≥10%, the presence
of serum and/or urinary monoclonal protein and evidence
of end-organ damage that can be attributed to the under-
lying plasma cell proliferative disorder, were excluded [27].
The following HDM/SCT inclusion criteria were ap-
plied: age between 18 and 65 years, performance status
of 0 to 2 according to Eastern Cooperative Oncology
Group (ECOG) criteria [28], a left ventricular ejection
fraction (LVEF) >45%, a serum bilirubin level ≤2.0 mg/dl, a
pulmonary diffusion capacity ≥50% and a serum creatinine
level ≤2 mg/dl. Patients were excluded if they had un-
compensated congestive heart failure, symptomatic cardiac
arrhythmia, or cardiac syncope.
Study design
In this prospective, randomized controlled study, newly
diagnosed AL amyloidosis patients who met the cri-
teria for HDM/SCT were randomized to receive two
cycles of BD as induction therapy followed by HDM/
SCT (BD +HDM/SCT) or to receive HDM/SCT alone as
an initial treatment. The BD regimen included bortezomib
1.3 mg/m2 i.v. and dexamethasone 40 mg p.o. on days 1,
4, 8 and 11 of the 21 day cycle. This process was repeated
for two cycles, after which the patients underwent HDM/
SCT treatment within eight weeks. The stem cells were
mobilized with granulocyte colony-stimulating factor alone,
and a minimum collection of 2 × 106 CD34+/kg body
weight was required. The patients were assigned to one of
two MEL dose levels (200 mg/m2 or 140 mg/m2) based on
age, cardiac involvement and renal function [29] (Figure 1).
Supportive therapy for side effect management was admin-
istered according to the clinical requirements. Omeprazole
was given as prophylaxis to all patients who received
BD induction, but they were not treated with anti-virus
prophylaxis. The patients were assessed every three
months following HDM/SCT until progression or death.
Adverse events (AEs) were recorded throughout the
study and were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events, version 3.0.
Hematologic and organ response criteria
Hematologic and organ responses were evaluated according
to the novel criteria of the International Society of
Amyloidosis [30,31] . Hematologic complete response
(CR) was defined as normalization of the FLC levels
and ratio, negative serum and urine immunofixation.
A hematologic very good partial response (VGPR) was
Figure 1 Study schema.
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involved FLCs and uninvolved FLCs) to <40 mg/L. A
hematologic partial response (PR) was defined as a
greater than 50% reduction in dFLCs. No response
(NR) was defined as less than PR. A hematologic pro-
gression has three situations: from CR, any detectable
monoclonal protein or abnormal FLC ratio (the light
chain must double); from PR, a 50% increase in serum
M protein to >0.5 g/dl or 50% increase in urine M protein
to >200 mg/day (a visible peak must be present); and an
FLC increase of 50% to >100 mg/l. The hematological
and organ responses were assessed every three months
following HDM/SCT.
Statistical analysis
The protocol was designed as a superiority trial to
demonstrate that BD induction followed by HDM/SCT
is superior to HDM/SCT alone for treating AL amyl-
oidosis. The working hypothesis was that the BD in-
duction, followed by the HDM/SCT, would improve
the hematologic CR rate (estimated to be 30% in the
group assigned to receive the HDM/SCT alone) by 40%
at 12 months. The sample size necessary to detect a
significant difference (α = 0.05, 2-sided) was calculated
to be 23 on the basis of 0.8 power. To compensate for the
non-assessable patients, we planned to enroll a minimum
of 28 patients per group.
The primary end point for this study was a hematologic
CR rate 12 months after HDM/SCT. The secondary end
points included the organ response rate, overall survival
(OS), and progression free survival (PFS) for all patients.
OS was defined as the time from the randomization to
the date of death from any cause. The survival time was
censored at the date of the last contact for the patientswho were still alive or lost to follow-up. PFS was defined as
the time from the randomization until date of progression,
death, or last follow-up. The PFS and OS between the
groups were compared using the Kaplan-Meier method.
The start date was the date of randomization, and the
cutoff date was June 30, 2013.
The t-test for independent samples or the Mann–
Whitney U test was used to compare the continuous data
between the groups. The differences between the categor-
ical variables were assessed using Fisher’s exact test. Cox
proportional hazards were used to calculate the hazard
ratios (HRs) for each variable. The P value reported was
2-sided, and P <0.05 was considered to be statistically
significant. All analyses were performed using SPSS soft-
ware (version 13.0, SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Between June 2009 and June 2012, 56 patients (Table 1)
with newly diagnosed, treatment-naive AL amyloidosis who
provided informed consent were enrolled and treated in
this clinical trial. A total of 28 patients were treated with
BD induction followed by HDM/SCT (BD +HDM/SCT),
while another 28 patients received only HDM/SCT. The
median ages and gender compositions of the patients in the
two groups were similar. The median time from diagnosis
to transplantation was four months (range, 2 to 16 months)
in the BD + HDM/SCT group and two months (range,
1 to 18 months) in the HDM/SCT group (P = 0.07).
The frequencies of systemic involvement were similar in
both groups, and all patients presented with renal involve-
ment, as confirmed by renal biopsy. A total of 17 patients
(60.7%) in the BD +HDM/SCT group and 16 patients
(57.1%) in the HDM/SCT group had involvement of more
Table 1 Patient characteristics
Characteristic BD + HDM/SCT (number = 28) HDM/SCT (number = 28) P value
Age (years)
Median 53 51.5 0.23
Range 38-65 37-63
Male/female (number) 18/10 16/12 0.78
Organ involvement, number (%)
Kidney 28 (100) 28 (100) 1.0
Heart 17 (60.7) 15 (53.5) 0.79
Liver 1 (3.6) 3 (10.7) 0.61
Nervous system 3 (10.7) 2 (7.1) 1.0
>1 organ involved 17 (60.7) 16 (57.1) 1.0
Cardiac stage, number (%)a
I 14 (50) 12 (42.9) 0.86
II 10 (35.7) 11 (39.3)
III 4 (14.3) 5 (17.8)
Involved FLC, number (%)
κ 3 (10.7) 2 (7.1) 1.0
λ 25 (89.3) 26 (92.9)
Abnormal FLC κ-to-λ ratio number (%) 26 (92.9) 27 (96.4) 1.0
ECOG PS (0/1/2), number (%)
0 13 (44.4) 14 (46.2) 0.75
1 10 (37) 11 (42.3)
2 5 (18.6) 3 (11.5)
24-hour urine protein (g/24 hour) 4.6 ± 2.2 5.8 ± 4.1 0.18
Albumin (g/L) 26.8 ± 6.1 25.7 ± 4.9 0.44
Creatinine (mg/dL) 0.8 ± 0.3 0.8 ± 0.4 0.72
GFR (mL/min) 89.0 ± 19.6 85.1 ± 25.6 0.53
Marrow plasma cells (%) 3.2 ± 2.7 2.8 ± 2.1 0.59
Echocardiogram septal thickness (mm) 11.7 ± 2.4 11.1 ± 1.8 0.33
Ejection fraction (%) 60.8 ± 6.5 62.7 ± 6.1 0.27
Alkaline phosphatasea (U/L)
Median 58 49 0.11
Range 23 to 321 33 to 661
NT-proBNP (ng/L)
Median 268 249 0.32
Range 55.5 to 13,730 15.2 to 7,709
>8500 ng/L (%) 1 (3.6) 1 (3.6)
BNP (ng/L)
Median 117 120 0.85
Range 22 to 3,261 17 to 3,078
Troponin-I (ng/ml)
Median 0.003 0.003 0.83
Range 0 to 0.15 0 to 0.12
iFLC (mg/L)
Median 114.9 97.8 0.15
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Table 1 Patient characteristics (Continued)
Range 25 to 516 24 to 204
dFLC (mg/L)
Median 96.1 64.8 0,12
Range 14 to 471 14 to 163
>180 mg/L (%) 2 (7.1) 0
aThe upper reference limit for alkaline phosphatase is 172 U/L. BNP, brain natriuretic peptide; ECOG PS, Eastern Cooperative Oncology Group performance status;
FLC, free light chain; GFR, glomerular filtration rate.
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the BD +HDM/SCT and HDM/SCT group was 60.7% and
53.5%, respectively; using biomarker cardiac staging cri-
teria [32], the proportion of stage I, II, and III patients
in the two groups were 50% versus 42.9%, 35.7% versus
39.3%, and 14.3% versus 17.8%, respectively. The labora-
tory findings for both groups demonstrated that nephrotic
syndrome was the main clinical feature presented by all
patients, and that there were no differences between the
two groups at the time of diagnosis. BD induction therapy
has been reported to quickly reduce the levels of involved
FLCs (iFLCs) and dFLCs. Accordingly, the median values
of iFLCs and dFLCs in the BD +HDM/SCT group had de-
creased by more than 50% prior to HDM/SCT.
Treatment
Of the 28 patients who underwent BD induction, 24
completed the treatment in accordance with the standard
dose; four patients developed neuropathy and one patient
experienced thrombocytopenia resulting in a dose reduc-
tion of bortezomib in the second cycle. Five patients
developed grade 3 edema, resulting in a dose reduction of
dexamethasone to 20 mg. A total of 14 patients in the
BD +HDM/SCT group and 13 patients in the HDM/SCT
group received 200 mg/m2 MEL whereas the other patients
received 140 mg/m2 MEL (Figure 1). The median number
of stem cells collected was 5.5 × 106 CD34+/kg (range: 2 to
13.7 × 106 CD34+/kg) in the BD + HDM/SCT group and
3.5 × 106 CD34+/kg (range: 2.0 to 14.2 × 106CD34+/kg)
in the HDM/SCT group (P = 0.13). The median granulo-
cyte and platelet engraftment was 10 days and 13 days,
respectively.
Hematologic and organ responses
The hematologic responses and organ response rate are
summarized in Table 2. The hematologic overall response
rate (ORR) between the BD+HDM/SCT arm and HDM/
SCT arm at three, six and twelve months was 78.5% versus
50%, 82.1% versus 53.5% and 85.7% versus 53.5%, respect-
ively, and the CR at three, six and twelve months was
53.6% versus 21.4%, 60.7% versus 28.5% and 67.9% versus
35.7%, respectively. The intention-to-treat (ITT) response
rates calculated at 24 months in 20 and 23 patients for
the BD + HDM/SCT and HDM/SCT arm were 80% and47.8%, respectively. There were significant differences
in hematologic CR among the patients who were evaluated
a year after completing transplantation in the BD +HDM/
SCT group and the HDM/SCT group, at 67.9% in the
former and 35.7% in the latter (P = 0.02). The 12-month
ORRs were also higher in the BD + HDM/SCT group
(85.7% versus 53.6%, P = 0.04), and this group also had
higher CR rates at 3, 6 and 24 months. No significant
difference was observed between the two groups with
respect to the VGPR and PR and the disease progression
(PD) rates. A total of 15 patients achieved hematologic
response after induction therapy in the BD + HDM/SCT
group, of whom eleven patients (39.2%) achieved CR,
two achieved VGPR, and two achieved PR. ORR after
BD and prior to HDM/SCT in the BD + HDM/SCT arm
was 53.5%; seven of the other thirteen BD + HDM/SCT
patients who exhibited NR to induction therapy achieved
hematologic response at three months post-transplantation
(two patients achieved CR, two patients achieved VGPR,
and three patients achieved PR).
The ITT analysis of organ response (OR) between the
two groups is also summarized in Table 2. A total of
65.2% (n = 15) of the patients in the BD +HDM/SCT
group and 39.1% (n = 9) of patients in the HDM/SCTgroup
experienced improvements in at least one involved organ
by twelve months. When assessed by individual organ, the
response rates of the kidneys and hearts in the BD+HDM/
SCT patients were higher than those of the HDM/SCT
patients. However, the response rates of the liver and
nervous system were similar between the two groups.
In both groups, the OR rates of the surviving patients
gradually increased with follow-up time.
Survival and progression
The median follow-up of the surviving patients was
28 months (range 12 to 8 months), and the data collection
for the median PFS and OS is ongoing. The Kaplan-Meier
curves for the PFS and OS are shown in Figure 2. Eight
patients (two patients from the BD + HDM/SCT group
and six patients from the HDM/SCT group) died during
the follow-up period. One of these patients died from
gastrointestinal bleeding, one died from sepsis, and the
others died because of complications related to the
progression of the disease. All patients who achieved
Table 2 Hematological and organ responses
ITT Months post HDM/SCT
3 3 12 12 24 24
BD + HDM/SCT HDM/SCT BD + HDM/SCT HDM/SCT BD + HDM/SCT HDM/SCT
Number = 28 Number = 28 Number = 28 Number = 28 Number = 20 Number = 23
CR 15 (53.6%)a 6 (21.4%) 19 (67.9%)a 10 (35.7%) 14 (70%)a 8 (34.8%)
VGPR 4 (14.3%) 4 (14.3%) 2 (7.1%) 3 (10.7%) 1 (5%) 1(4.3%)
PR 3 (10.7%) 4 (14.3%) 3 (10.7%) 2(2.1%) 1 (5%) 2 (8.7%)
NR 6 (21.4%) 12 (42.8%) 2 (7.1%) 6 (21.4%) 2 (10%) 3 (13.0%)
PD - - 2 (7.1%) 3 (10.7%) 1 (5%) 3 (13.0%)
Organ responses
Kidneyb 65.2% (15/23) 39.1% (9/23) 75% (12/16) 53.8% (7/13)
Heartb 67% (10/15) 25% (4/12) 70% (7/10) 50% (3/6)
Liverb 100% (1/1) 50% (1/2) 100% (1/1) 100% (1/1)
NSb 100% (3/3) 100% (2/2) 100% (3/3) 100% (2/2)
aCompared with the HDM/SCT group, P <0.05; bevaluable patients. CR, complete hematological response; ITT, intention-to-treat; NR, no response; NS, nervous
system; PD, disease progression; PR, partial response; SD, stable disease; VGPR, very good partial response.
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SCT group and six patients in the HDM/SCT group
had hematologic progression during the follow-up period.
Two BD + HDM/SCT patients and three HDM/SCT
patients received second-line treatment based on bortezo-
mib or thalidomide, but only one of these patients had
a hematologic (partial) response.
PFS and OS differed significantly between the two groups
(Figure 2A and B). The patients in the BD + HDM/SCT
group had better PFS and OS rates than the patients in theFigure 2 Progression free survival and overall survival. (A) The PFS of
rates of the two groups; and (D) The OS of all patients based on the MayoHDM/SCT group. The estimated OS of the patients at
24 months was 95.0% in the BD +HDM/SCT group and
69.4% in the HDM/SCT group (P = 0.03); the estimated
PFS of patients at 24 months was 80.7% in the BD +HDM/
SCT group and 51.1% in the HDM/SCT group (P = 0.01).
The renal survival (Figure 2C) at 24 months was 91.4% in
the BD+HDM/SCT group and 62.6% in the HDM/SCT
group (P = 0.02). Based on the Mayo cardiac staging system,
those patients with stage III cardiac involvement had
the worst OS rate (Figure 2D), and the median survivalthe two groups; (B) the OS of the two groups; (C) the renal survival
cardiac staging system.
Table 4 Adverse events possibly related to HDM/SCT
(Grade >2)





Nausea or vomiting 8 (28.6%) 10 (35.7%) 0.78
Diarrhea 6 (21.4%) 7 (25%) 1.0
Mucositis 5 (17.9%) 7 (25%) 0.75
Hepatic 5 (17.9%) 5 (17.9%) 1.0
Renal 4 (14.3%) 6 (21.4%) 0.73
Cardiac 3 (10.7%) 6 (21.4%) 0.47
Febrile neutropenia 9 (32.1%) 7 (25%) 0.77
Sepsis 0 2 (7.1%) 0.5
BD, bortezomib in combination with dexamethasone; HDM/SCT, high dose
melphalan and autologous stem cell transplantation.
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(HR, 6.138; 95% confidence interval (CI), 1.559 to 24.170;
P = 0.009) was independently associated with survival
(Table 3).
Treatment-related mortality and toxicity
In total, two patients died within 100 days post-
transplantation, resulting in a TRM of 3.6%. Both pa-
tients were in the HDM/SCT group: one death was
cardiac related, occurring at +60 days, and the other
death was caused by hepatic rupture, which occurred
at +21 days. The treatment-related toxicities were similar
between the two groups (Table 4), with gastrointestinal
toxicity as the most common AE. The grade 3 and 4 AEs
that were possibly related to BD induction are shown in
Table 5. The hematological adverse events (grade 3 and 4)
included 34% thrombocytopenia, 15% anemia and 7%
neutropenia. The most common non-hematologic BD
toxicity was infection (n = 8), while herpes zoster infection
was the most common type (n = 5). Edema was also a com-
mon toxicity during BD treatment: 17.9% (n = 5) patients
developed grade 3 edema.
Discussion
The HDM/SCT procedure for AL amyloidosis was in-
troduced in 1998 by Comenzo et al., and represented a
major breakthrough for AL amyloidosis [33]. Indeed
accumulating data have indicated that HDM/SCT can
suppress underlying monoclonal plasma cell disease
and improve the patient’s quality of life [34]. The pur-
pose of induction chemotherapy is to reduce the light
chain load and to improve organ function prior to
HDM/SCT. Amyloidosis is characterized by a relatively
small tumor mass, so small that induction chemotherapy
is often not necessary before proceeding directly to high-
dose therapy. To date, the use of induction chemotherapy
prior to HDM/SCT has been evaluated in a few studies,
which have reported negative results. Pretreatment
with two cycles of oral melphalan/prednisone prior to
the transplantation did not improve the results of a
prospective randomized trial [35]. Similarly, the data from
Perz et al. [36] indicated that administering vincristine,Table 3 Factors associated with survival of all patients
Factors Univariate
HR 95% CI
Without BD induction 4.730 1.003-22.307
Urine protein >3.5 g/24 hour 1.2 0.310-4.647
Cardiac stage III 4.118 1.138-14.899
Baseline BNP >170 ng/L 2.837 0.814-9.892
Troponin-I >0.03 6.494 1.673-25.213
The use of MEL 140 3.445 0.730-16.255
BD, bortezomib in combination wity dexamethasone; BNP, brain natriuretic peptidedoxorubicin and dexamethasone (VAD) before HDM/
SCT did not increase the hematologic response rate.
Nonetheless, the outcome of BD induction prior to
HDM/SCT has remained unknown.
Several studies have reported the results of adjuvant BD
combination with HDM/SCT, and the addition of borte-
zomib to the HDM used as a conditioning regimen prior
to stem-cell transplantation is feasible and well-tolerated
by patients with AL amyloidosis [37]. The BD regimen
has also been used following HDM/SCT to improve the
depth of the response for patients who achieve less than
VGPR. Nineteen of 28 patients received post-transplant
BD chemotherapy, with 67% of these achieving CR and
60% organ responses [38]. A complementary approach
of administering two cycles of BD prior to and as condi-
tioning for HDM/SCT also yielded very good response
rates of hematological remission in 9/18 patients after the
induction, and all 11 patients evaluable after HDM/SCT
attained CR/VGPR [39]. The combination of BD with
cyclophosphamide has also shown encouraging response
rates in patients with AL amyloidosis, even without
high-dose therapy [40,41]. Additionally, most of the
patients in these two series were either transplant in-
eligible or relapsed. Therefore, based on the current
knowledge regarding the use of BD in the treatment of AL
amyloidosis, it is clear that the BD regimen is effective andMultivariate
P HR 95% CI P
0.050 4.359 0.913-20.823 0.065
0.792
0.031 1.272 0.276-5.864 0.758
0.104
0.007 6.138 1.559-24.170 0.009
0.118
; CI, confidence interval; HR, hazard ratio; MEL, melphalan.
Table 5 Adverse events possibly related to BD induction
Toxicity Grade 3 Grade 4 Grade 5
Thrombocytopenia, number (%) 8 (28.6%) 1 (3.6%) 0
Neutropenia, number (%) 2 (7.1%) 0 0
Anemia, number (%) 4 (14.3%) 0 0
Gastrointestinal, number (%) 7 (25%) 0 0
Cardiac, number (%) 3 (10.7%) 0 0
Infection, number (%) 8 (28.6%) 0 0
Acute kidney injury, number (%) 2 (7.1%) 0 0
Hepatic, number (%) 3 (10.7%) 0 0
Neuropathy 5 (17.9%) 0 0
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show that BD therapy prior to HDM/SCT can quickly
reduce the FLC level and the tumor burden and can
furthermore delay the progress of involved organs, thus im-
proving the safety and efficiency of HDM/SCT. Therefore,
the BD regimen is an appropriate therapy before HDM/
SCT. For patients who have already achieved CR prior to
HDM/SCT, it is difficult to assess whether HDM/SCT was
necessary, and only a clinical trial can provide an answer.
Regardless, we believe that additional therapy with HDM/
SCT may be able to improve the depth of the response
and further extend PFS of those patients.
Our data demonstrate that BD induction followed by
risk-adapted HDM/SCT is a more effective strategy than
HDM/SCT alone for treating newly diagnosed patients
with AL amyloidosis. The majority of patients (85.7%)
in the BD induction group achieved hematological re-
sponses, including more than half (67.9%) who achieved
CR at one year post-therapy. The BD induction group
also displayed better PFS and OS rates than the group
that received HDM/SCT alone. HDM/SCT treatment in
patients with cardiac involvement remains challenging,
particularly for patients with stage III cardiac involve-
ment. In our series, 44.4% (4/9) of the patients with
stage III cardiac involvement died during follow-up, but
the median survival time was more favorable than previ-
ously reported [32].
The disadvantages of induction chemotherapy in pa-
tients with AL amyloidosis include the potential risk of
side effects, the risk of further worsening organ function
and the consequent delay of HDM/SCT. Our data demon-
strate that the majority of patients can tolerate two cycles
of BD treatment, and that the toxicity of the BD regimen
is moderate and manageable. All toxicities were reversible
and did not influence the subsequent HDM/SCT proced-
ure because MEL toxicity differs from that of bortezomib.
However, additional attention should be given to some
toxicities that can result in bortezomib or dexamethasone
dose reduction, including edema, peripheral neuropathy,
and thrombocytopenia. Edema is a common toxicity forhigh-dose dexamethasone, particularly in patients with
renal involvement and low serum albumin levels. Because
the serum albumin levels of all five patients who devel-
oped grade 3 edema were lower than 2 g/dl, support treat-
ment with diuretics and serum albumin is important for
these patients. Peripheral neuropathy also needs to be
carefully monitored during BD induction, as 18% of the
patients developed grade 3 neuropathy in this study, ap-
parently higher than in other studies [24,25]. One study
demonstrated that 1.6 mg/m2 once-weekly bortezomib
dosing can reduce toxicity compared to 1.3 mg/m2 twice-
weekly dosing [42]. Subcutaneous bortezomib is another
option to reduce the incidence of peripheral neuropathy
and has been confirmed in a randomized, phase 3 study
for multiple myeloma patients [43] and was also proven in
a small series of AL amyloidosis patients [44]. In addition,
we observed a high incidence of herpes zoster infection
during BD induction; thus, anti-virus prophylaxis appears
to be necessary for these patients. In our study, the occur-
rence of TRM in our study population of 56 patients was
3.6% (2/56), a lower value than in most reports. Moreover,
no patients in the BD induction group died because of
treatment-related complications. The possible reasons for
the relatively low TRM observed include the risk-adapted
approach of HDM/SCT, the induction chemotherapy used
in half of the patients, the small proportion of patients
with severe cardiac involvement and racial differences.
This study has several limitations. First, all of the patients
had renal involvement, which most likely constitutes a se-
lection bias because the study was conducted in a nephrol-
ogy institution. Second, neither group met the median PFS
and OS rates, and the long-term patient prognosis requires
further study. Third, it is unclear whether the PFS rate of
the patients who achieved CR after the BD induction fol-
lowing HDM/SCT is equivalent to the CR achieved with
BD therapy alone. Fourth, the sample size of this trial is too
small to allow patient stratification based on known risk
factors, as well as to allow a subgroup analysis, so the re-
sults for stratification or subgroup analysis cannot match
the results of other studies. We will continue this study and
enroll more patients to make this stratification or subgroup
analysis more clear. Additionally, the appropriate salvage
regimen for patients who had no response to BD induction
following HDM/SCT is also unclear.
Conclusions
In conclusion, our preliminary data suggest that induction
therapy with BD followed by HDM/SCT is an effective
and tolerable regimen for treating patients with AL amyl-
oidosis. This protocol can significantly improve both the
hematological and organ response rates, and the risk of
the BD + HDM/SCT regimen is apparently comparable
to that of HDM/SCT. Although HDM/SCT remains a
high-risk treatment modality for AL amyloidosis, new
Huang et al. BMC Medicine 2014, 12:2 Page 9 of 10
http://www.biomedcentral.com/1741-7015/12/2agents, such as bortezomib, may alter this therapeutic
approach and improve patient outcomes. Further study
will be required to establish the long-term benefits of
this treatment.
Abbreviations
AEs: adverse events; BD: bortezomib in combination with dexamethasone;
BNP: brain natriuretic protein; CR: complete response; ECOG: Eastern
Cooperative Oncology Group; FLC: free light chains; HDM/SCT: high dose
melphalan and autologous stem cell transplantation; HRs: hazard ratios;
ITT: intention to treat; MEL: melphalan; NR: no response; OR: organ response;
ORR: overall response rate; OS: overall survival; PD: disease progression;
PFS: progression free survival; PR: partial response; TRM: treatment-related
mortality; VAD: vincristine doxorubicin and dexamethasone; VGPR: very good
partial response.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZL, XH and QW designed and performed the research, analyzed the data
and wrote the paper. WC performed research and analyzed data. XH, QW,
WC, CZ, ZC, DG, HZ and ZL took care of the patients. All of the authors read
and approved the final manuscript.
Acknowledgments
Part of this work was presented as a poster at the 2013 World Congress of
Nephrology in Hong Kong, China, 31 May to 4 June 2013. This work was
supported by the National Key Technology R&D Program (No. 2013BAI09B04)
and the Clinical Research Program of Jiangsu Province (No. BL2012007).
Received: 20 September 2013 Accepted: 6 December 2013
Published: 6 January 2014
References
1. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med
2003, 349:583–596.
2. Comenzo RL: Amyloidosis. Curr Treat Options Oncol 2006, 7:225–236.
3. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM:
Long-term survival (10 years or more) in 30 patients with primary
amyloidosis. Blood 1999, 93:1062–1066.
4. Palladini G, Merlini G: Current treatment of AL amyloidosis. Haematologica
2009, 94:1044–1048.
5. Rajkumar SV, Gertz MA: Advances in the treatment of amyloidosis.
N Engl J Med 2007, 356:2413–2415.
6. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA: Prospective
randomized trial of melphalan and prednisone versus vincristine,
carmustine, melphalan, cyclophosphamide, and prednisone in the
treatment of primary systemic amyloidosis. J Clin Oncol 1999, 17:262–267.
7. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, Jones LA, Cohen
AS: Treatment of 100 patients with primary amyloidosis: a randomized
trial of melphalan, prednisone, and colchicine versus colchicine only.
Am J Med 1996, 100:290–298.
8. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G,
Rustichelli R, Virga G, Merlini G: Association of melphalan and high-dose dexa-
methasone is effective and well tolerated in patients with AL (primary) amyloid-
osis who are ineligible for stem cell transplantation. Blood 2004, 103:2936–2938.
9. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L, Merlini G:
Treatment with oral melphalan plus dexamethasone produces long-term
remissions in AL amyloidosis. Blood 2007, 110:787–788.
10. Gertz MA: Immunoglobulin light chain amyloidosis: 2013 update on
diagnosis, prognosis, and treatment. Am J Hematol 2013, 88:416–425.
11. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson
JJ, O’Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG:
High-dose melphalan and autologous stem-cell transplantation in patients
with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85–93.
12. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N,
Gastineau DA: Effect of hematologic response on outcome of patients
undergoing transplantation for primary amyloidosis: importance of
achieving a complete response. Haematologica 2007, 92:1415–1418.13. Gertz MA, Lacy MQ, Dispenzieri A:Myeloablative chemotherapy with stem cell
rescue for the treatment of primary systemic amyloidosis: a status report.
Bone Marrow Transplant 2000, 25:465–470.
14. Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J,
Quillen K, Skinner M: An overview of the use of high-dose melphalan with
autologous stem cell transplantation for the treatment of AL amyloidosis.
Bone Marrow Transplant 2001, 28:637–642.
15. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, Hermine O,
Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N,
Harousseau JL: Prognostic factors for survival and response after high-dose
therapy and autologous stem cell transplantation in systemic AL amyloidosis:
a report on 21 patients. Br J Haematol 1998, 101:766–769.
16. Palladini G, Merlini G: Transplantation vs. conventional-dose therapy for
amyloidosis. Curr Opin Oncol 2011, 23:214–220.
17. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R,
Comotti B, Merlini G: The combination of thalidomide and intermediate-dose
dexamethasone is an effective but toxic treatment for patients with primary
amyloidosis (AL). Blood 2005, 105:2949–2951.
18. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore
JD: Safety and efficacy of risk-adapted cyclophosphamide, thalidomide,
and dexamethasone in systemic AL amyloidosis. Blood 2007, 109:457–464.
19. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB,
Skinner M, Seldin DC: Lenalidomide and dexamethasone in the treatment
of AL amyloidosis: results of a phase 2 trial. Blood 2007, 109:492–496.
20. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C,
Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E,
Nanas J, Dimopoulos MA: Treatment of light chain (AL) amyloidosis with
the combination of bortezomib and dexamethasone. Haematologica
2007, 92:1351–1358.
21. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T,
Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel
JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter
JB, Schenkein D, Anderson KC: Bortezomib or high-dose dexamethasone for
relapsed multiple myeloma. N Engl J Med 2005, 352:2487–2498.
22. San MJ, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka
I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM,
Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van
de Velde H, Richardson PG: Bortezomib plus melphalan and prednisone for
initial treatment of multiple myeloma. N Engl J Med 2008, 359:906–917.
23. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD: Efficacy of
bortezomib in systemic AL amyloidosis with relapsed/refractory clonal
disease. Haematologica 2008, 93:295–298.
24. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP,
Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL:Weekly and twice-weekly
bortezomib in patients with systemic AL amyloidosis: results of a phase 1
dose-escalation study. Blood 2009, 114:1489–1497.
25. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V,
Gillmore JD, Palladini G: Bortezomib with or without dexamethasone in
primary systemic (light chain) amyloidosis. J Clin Oncol 2010, 28:1031–1037.
26. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN,
Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau
G: Definition of organ involvement and treatment response in
immunoglobulin light chain amyloidosis (AL): a consensus opinion from
the 10th International Symposium on Amyloid and Amyloidosis, Tours,
France, 18–22 April 2004. Am J Hematol 2005, 79:319–328.
27. Kyle RA, Rajkumar SV: Criteria for diagnosis, staging, risk stratification and
response assessment of multiple myeloma. Leukemia 2009, 23:3–9.
28. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET,
Carbone PP: Toxicity and response criteria of the Eastern Cooperative
Oncology Group. Am J Clin Oncol 1982, 5:649–655.
29. Comenzo RL, Gertz MA: Autologous stem cell transplantation for primary
systemic amyloidosis. Blood 2002, 99:4276–4282.
30. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN,
Schonland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard
A, Klersy C, Merlini G: New criteria for response to treatment in
immunoglobulin light chain amyloidosis based on free light chain
measurement and cardiac biomarkers: impact on survival outcomes.
J Clin Oncol 2012, 30:4541–4549.
31. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk
R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M,
Streicher H, Skinner M, Kyle RA, Merlini G: Consensus guidelines for the
Huang et al. BMC Medicine 2014, 12:2 Page 10 of 10
http://www.biomedcentral.com/1741-7015/12/2conduct and reporting of clinical trials in systemic light-chain amyloidosis.
Leukemia 2012, 26:2317–2325.
32. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR,
Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS:
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging
system for primary systemic amyloidosis. J Clin Oncol 2004, 22:3751–3757.
33. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K,
Dubrey S, Faller DV, Wright DG, Falk RH, Skinner M: Dose-intensive melphalan
with blood stem cell support for the treatment of AL amyloidosis: one-year
follow-up in five patients. Blood 1996, 88:2801–2806.
34. Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, Finn
KT, Berk JL, Dember LM, Falk RH, Skinner M: Improvement in quality of life
of patients with AL amyloidosis treated with high-dose melphalan and
autologous stem cell transplantation. Blood 2004, 104:1888–1893.
35. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM,
Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M: High-dose
intravenous melphalan and autologous stem cell transplantation as
initial therapy or following two cycles of oral chemotherapy for the
treatment of AL amyloidosis: results of a prospective randomized
trial. Bone Marrow Transplant 2004, 33:381–388.
36. Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke
RP, Ho AD, Goldschmidt H: High-dose melphalan with autologous stem
cell transplantation after VAD induction chemotherapy for treatment of
amyloid light chain amyloidosis: a single centre prospective phase II
study. Br J Haematol 2004, 127:543–551.
37. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC: Bortezomib
and high-dose melphalan conditioning for stem cell transplantation for
AL amyloidosis: a pilot study. Haematologica 2011, 96:1890–1892.
38. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C, Bello
C, Hoover E, Riedel E, Giralt S, Comenzo RL: Bortezomib and
dexamethasone consolidation following risk-adapted melphalan and
stem cell transplantation for patients with newly diagnosed light-chain
amyloidosis. Leukemia 2013, 27:823–828.
39. Sanchorawala V, Alam M, Shelton A, Brauneis D, Andrea NT, Sloan JM, Seldin
DC: Treatment of AL amyloidosis with 2 cycles of induction therapy with
bortezomib and dexamethasone followed by bortezomib-high dose
melphalan conditioning and autologous stem cell transplantation. XIIIth
International Symposium on Amyloidosis, 2012. PC53.
40. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart
AK, Bergsagel PL, Fonseca R: Cyclophosphamide-bortezomib-dexamethasone
(CyBorD) produces rapid and complete hematologic response in patients
with AL amyloidosis. Blood 2012, 119:4391–4394.
41. Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ,
Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD:
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL
amyloidosis is associated with high clonal response rates and prolonged
progression-free survival. Blood 2012, 119:4387–4390.
42. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J,
Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL,
van de Velde H, Cakana A, Comenzo RL: Efficacy and safety of once-weekly
and twice-weekly bortezomib in patients with relapsed systemic AL
amyloidosis: results of a phase 1/2 study. Blood 2011, 118:865–873.
43. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M,
Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J,
Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL:
Subcutaneous versus intravenous administration of bortezomib in patients
with relapsed multiple myeloma: a randomised, phase 3, non-inferiority
study. Lancet Oncol 2011, 12:431–440.
44. Shah G, Kaul E, Fallo S, Cossor F, Smith H, Sprague K, Klein A, Miller K, Comenzo R:
Bortezomib subcutaneous injection in combination regimens for myeloma or
systemic light-chain amyloidosis: a retrospective chart review of response
rates and toxicity in newly diagnosed patients. Clin Ther 2013, 35:1614–1620.
doi:10.1186/1741-7015-12-2
Cite this article as: Huang et al.: Induction therapy with bortezomib and
dexamethasone followed by autologous stem cell transplantation
versus autologous stem cell transplantation alone in the treatment of
renal AL amyloidosis: a randomized controlled trial. BMC Medicine
2014 12:2.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
